Abstract. There is increasing evidence that cancer contains cancer stem cells (CSCs) that are capable of regenerating a tumor following chemotherapy or radiotherapy. CD44 and CD133 are used to identify CSCs. This study investigated non-invasive in vivo monitoring of CD44-positive cancer stem-like cells in breast cancer by γ-irradiation using molecular image by fusing the firefly luciferase (fLuc) gene with the CD44 promoter. We generated a breast cancer cell line stably expressing fLuc gene by use of recombinant lentiviral vector controlled by CD44 promoter (MCF7-CL). Irradiated MCF7-CL spheres showed upregulated expression of CD44 and CD133, by immunofluorescence and flow cytometry. Also, gene expression levels of CSCs markers in irradiated spheres were clearly increased. CD44+ CSCs increased fLuc expression and tumor growth in vivo and in vitro. When MCF7-CL was treated with siCD44 and irradiated, CD44 expression was inhibited and cell survival ratio was decreased. MCF7-CL subsets were injected into the mice and irradiated by using a cobalt-60 source. Then, in vivo monitoring was performed to observe the bioluminescence imaging (BLI). When breast cancer was irradiated, relative BLI signal was increased, but tumor volume was decreased compared to non-irradiated tumor. These results indicate that increased CD44 expression, caused by general feature of CSCs by irradiation and sphere formation, can be monitored by using bioluminescence imaging. This system could be useful to evaluate CD44-expressed CSCs in breast cancer by BLI in vivo as well as in vitro for radiotherapy.

Introduction

Breast cancer is the most common cause of death in females among all malignant tumors. Currently, surgical treatment is mainly directed at primary treatment, chemotherapy, and radiotherapy, whereas targeted treatment aims to eliminate the residual tumor cells and thus mitigate the risk of recurrence and metastasis. Some patients, however, still relapse or metastasize after chemotherapy, radiotherapy, and targeted therapy (1).

Cancer cell propagation in tumor can ultimately acquire a capacity for self-renewal and can have multi-lineage potency for cancer organization. A very small population in cancer has these characteristics (2-4). The existence of breast cancer stem cells (BCSCs) in malignant breast tumors has been demonstrated in many previous studies (5,6). BCSCs exhibit a range of phenotypes, including CD44+/CD24- in breast cancer cells (7). The radio-resistance of BCSCs have more increased spheres than in monolayer, and the spheres have demonstrated enrichment of CD44+/CD24- cells (8,9). The radio-resistance of CSCs has also been demonstrated in mouse mammary progenitor cells, with an increase of progenitor cells with the characteristic stem cell surface markers following radiation of primary BALB/c mouse mammary epithelial cells (7,10). Discovery of BCSCs has thus opened up several potential approaches for breast cancer treatment and diagnosis. Thus, it is becoming increasingly important to identify, track, and target BCSCs in vivo. CSCs have been identified based on the expression, their lack of surface markers such as CD44, CD24, CD29, Lin, CD133, and Sca-1 (11).

CD44, ubiquitous multi-structural and multifunctional adhesion molecule, is a cell surface transmembrane glycoprotein in cell-cell and cell-matrix interactions (5). Previous studies on CD44’s role in breast tumor invasion demonstrated that CD44-mediated adhesion and signaling are required for cell growth, and the dissemination of breast tumors and CD44 can promote breast tumor cell invasion in vitro and in vivo (12-16).

Bioluminescence imaging (BLI) is a commonly-used method to measure transgene expression in vivo (17-19). BLI application to high throughput screening and imaging of cell
functions in intact animals makes the technique particularly versatile and attractive (20). In vivo imaging for CSCs, by using molecular imaging methods such as BLI, will provide information on CSC populations, tracking, or characteristics in cancer. Evaluation of CSCs in cancer therapy will give significant help to overcome the recurrence or metastasis of the cancer, or failure of cancer treatment.

In this study, we investigated non-invasive in vivo monitoring of CD44-positive cancer stem-like cells in breast cancer model by γ-irradiation using molecular imaging by fusing the firefly luciferase (Fluc) gene with the CD44 promoter.

Materials and methods

Animal care and the experimental procedures in this study were approved by the Animal Care and Ethics Committee at Korea Institute of Radiological and Medical Sciences (Seoul, Korea).

Cell culture. Human breast cancer cell lines, MCF7 and MCF7-CL were maintained in RPMI-1640 (WelGENE Inc., Korea) containing 10% fetal bovine serum (FBS) and 1% antibiotics in a humidified incubator at 37°C with 5% CO₂.

Lentivirus reproduction. Recombinant lentivirus (pWPXL-CD44p-luc) vectors were produced with pWPXL lentiviral vector was deleted of GFP site by digesting (pWPXL-CD44p-luc) vectors were produced with pWPXL Lentivirus reproduction. Recombinant lentivirus (pWPXL-CD44p-luc) vectors were produced with pWPXL vector was deleted of GFP site by digesting with SalI and SpeI, and was inserted CD44P-luciferase site from CD44P-GL3 vector by digesting with SalI, XbaI. The recombinant vector was packaged using packaging plasmids, pMD2.G and psPAX2, by a Calcium Phosphate Transfection protocol. Briefly, cultured cells for transfection were prepared according to the manufacturer's protocol. We prepared PBS, 0.5% BSA, and 2 mM EDTA by diluting MACS BSA stock solution with washing buffer. For MACS, the single cells were resuspended with 80 µl of 0.5% BSA and 2 mM EDTA buffer/10⁷ cells, and 20 µl of microbeads/10⁷ cells was added for 15 min at 4°C. After washing with buffer, the cells were resuspended with ≤10⁶ cells/500 µl of buffer, cell suspension were applied onto the column into the magnetic bars and were washed 3 times. Columns were removed from the magnetic bar and were immediately pipetted with the buffer. Then, we obtained CD44-positive cells or CD24-negative cells. Isolated CD44-positive expression subset (cancer stem-like subset; CD44⁺) and CD44 low/negative expression subset (non-cancer stem-like subset; CD44⁻/⁻) were irradiated by dose and were cultured.

Flow cytometry analysis. The cultured cells were detached from the dish by adding a solution of 0.25% trypsin and 0.02% EDTA (Gibco, USA), and then by washing with PBS. A cell pellet was collected after centrifugation at 1,500 rpm for 3 min and then resuspended in test tubes containing PBS (1x10⁶ cells/ml). Fluorescence conjugated antibodies, CD24-PE, CD44-PE, and CD133-FITC (eBioscience, USA), were added to single cells for 30 min at 4°C. All samples were washed with PBS, and cells were fixed in 1% paraformaldehyde. Phenotypic analysis was performed with a flow cytometer (FACSCalibur, BD Biosciences, USA).

Immunofluorescence staining. Cells were cultured in 2-well chamber slides and fixed with 4% paraformaldehyde for 1 h at 4°C and acetone for 5 min at room temperature (RT). Fixed cells were washed with PBS and were blocked with 10% normal goat serum and 1% bovine serum albumin (BSA) for 1.5 h in RT. Slides were incubated with mouse anti-human CD44 antibody (monoclonal, Abcam Co., UK), rabbit anti-human CD133 antibody (polyclonal, Biorbyt Co., UK), and rabbit anti-humal IgG antibody (monoclonal, Abcam Co., UK) for 1.5 h in RT. After rinsing with PBS, FITC (goat anti-rabbit, polyclonal) or cyanine 3 (Cy3, goat anti-mouse, monoclonal) conjugated secondary antibody (Abcam Co.) was added to
slide and incubated for 2.5 h. After rinsing, the slides were mounted with mounting solution (Vectashield Mounting Medium with DAPI, Vector Labs, USA) and observed using an Olympus DP71 digital microscopic camera system (Olympus). All images were processed with Olympus analySIS Five software (Olympus Soft Image Solutions).

Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Total RNA was extracted from the cultures using TRI reagent (Molecular Research Center, USA). Five micrograms of total RNA were reverse transcribed, using superscript III reverse transcriptase (Invitrogen) and random hexamers to generate complementary DNA (cDNA). PCR was performed using a 20-µl reaction volume, 3 ng of final concentration of all reagents in the reactions and 30 cycling conditions (GeneAmp PCR System 9700, Applied Biosystems, USA) with primers (Table I). Signals of the PCR products were visualized with a gel documentation system (Uvitec, UK). The fold change in the ratio of each gene mRNA to total GAPDH mRNA was measured in ImageJ software (National Institutes of Health, USA) by boxing each band per representative image with the rectangular selection tool, and calculating the total area of the band in pixels. The total area of each gene mRNA band in pixels was normalized to the total area of the total GAPDH mRNA band in pixels.

Generation of tumor xenografts in nude mice. Female BALB/c nu/nu nude mice (6-week-old) were purchased from Nara Biotech (Korea). Mice were treated with 17β-estradiol tablets (Innovative Research of America, USA) before injection with cells for 48 h. MCF7-CL subsets were injected into the fourth mammary fat pad and MACS sorted cells were injected into the thigh of the hind legs. Subcutaneous or orthotopic tumors were generated from implanting 5x10⁶ cells. Irradiation into mice was a single dose of 6 Gy using a cobalt-60 source (Cobalt-60 Teletherapy Unit; Theratron T-780, Theratronics, Canada, dose rate 0.6 Gy/min). The mammary fat pad of the anesthetized mice bearing the tumor cells was placed in a 2x30-cm radiation field of a cobalt-60 source, whereas the rest of the body was shielded (19). The tumor volume was measured by a caliper.

In vivo imaging of CD44 promoter-bioluminescence labeled breast cancer cells. Bioluminescence imaging was performed with CCD camera mounted in a light-tight specimen chamber (IVIS200, Xenogen, USA). Mice were injected intraperitoneally with a 100-µl of 2.5 mg/100 µl aqueous solution of D-luciferin potassium salt and anesthetized with 2% isoflurane before the imaging. Imaging acquisition time was from 1 sec to 1 min, depending on the bioluminescence signal. Imaging and quantification of signals were obtained using the acquisition and analysis software Living Image V. 2.50 (Xenogen Corp.). To measure the intensities of the emitted light, the regions of interest (ROI) were drawn over the emitted region of target signal (total p/s/cm²/sr).

Immunohistochemistry. The xenograft tumors were isolated and frozen. All tissue samples were sectioned (Cryotome, Leica CM 1950, Leica Biosystems Nussloch GmbH) at 5 µm thickness and were attached to a slide. Sections had been dried and routinely fixed in 70% ethanol for 5 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in methanol for 20 min. The slides were washed with Tris-buffered saline (TBS). The 10% PBS was used for 1 h in order to block non-specific binding. Cells were cultured in 2-well chamber slides and fixed with 4% paraformaldehyde for 1 h at 4°C and acetone for 5 min at RT. Fixed cells were washed with PBS and were blocked with 10% normal goat serum and 1% BSA for 1.5 h at RT. Slides were incubated with the primary antibodies, mouse anti-human CD44 antibody, mouse anti-human luciferase antibody (monoclonal, Abcam Co.), and anti-mouse

| Table I. Primers used in RT-PCR analysis. | Gene | Primer sequence |
|-----------------------------|-------|----------------|
| NM_013230.2                | CD24  | 5'-GCTCCTACCCACGCAGATTT-3' |
|                           |       | 5'-GAGACCACGAAGAGACTGGC-3' |
| NM_000610.3                | CD44  | 5'-CCCCACGAACCCTACTGATG-3' |
|                           |       | 5'-CCAGGTGTTTCTTGCTCTCTTGG-3' |
| NM_001145848.1             | CD133 | 5'-AACAGTTTTGCCCCCAGGAA-3' |
|                           |       | 5'-GTTTGACAGATGCCACACTTT-3' |
| JN542721.1                 | Luciferase | 5'-GGCTTTTATGAGGATCTCTCT-3' |
|                           |       | 5'-CGCCTTGATTGACAAGGATGG-3' |
| NM_008084.2                | GAPDH | 5'-AGGCCGGTGCTGATGATGTC-3' |
|                           |       | 5'-TGCTGCTCCACACCTCTCT-3' |
| NM_002701.4                | OCT4  | 5'-TGATCCTCGGACCTTGCTAA-3' |
|                           |       | 5'-AACCACACTCGGACCACATC-3' |
| NM_0024865.2               | Nanog | 5'-GGATCCAGCTCTGCCCCAAA-3' |
|                           |       | 5'-TGACCAGGTCTGAGTGTCCTC-3' |
IgG antibody (monoclonal, Abcam Co.), in 1% BSA overnight at 4°C. After rinsing with TBS, horseradish peroxidase (HRP) conjugated secondary antibody (Dako Denmark, Denmark) was added to slide and incubated for 30 min. The slides were incubated and developed with Liquid DAB (3,3-diaminobenzidine tetrahydrochloride) substrate solution (Liquid DAB+Substrate Chromogen System, Dako North America, Inc. USA) for 2 min. After washing with tap water for 10 min, light Mayer's hematoxylin (Vector Laboratories, Inc., USA) was applied as a counterstain. After washing with tap water for 30 min, the slides were then dehydrated in a series of ethanol and mounted with permount mount media (Gel Mount aqueous mounting medium, Sigma, USA). The cell slides were observed using an Olympus DP71 digital microscopic camera system (Olympus). All images were processed with Olympus analySIS Five software (Olympus Soft Image Solutions).

**Statistical analysis.** Data are presented as means-standard errors of the mean. Statistical significance was performed using GraphPad PRISM (GraphPad Software, Inc., USA). Statistical significance was tested by using a Student's t-test, one-way ANOVA and two-way ANOVA. P<0.05 was considered to indicate a significant difference.

**Results**

**Increased CD44 expression by dosed γ-irradiation.** We generated MCF7-CL stably expression of CD44 promoter-luciferase gene using bioluminescence assay. When cell population increased, BLI signals and bioluminescence signals were increased (data not shown). After irradiation, bioluminescence signals were increased (Fig. 1A) and cell survival populations were decreased time-dependently (Fig. 1B). According to the increment of irradiation dose, cell survival population was decreased, but CD44 and fLuc gene expression was increased (Fig. 1C). The irradiated cell were recorded as 98% at 4 Gy, 31% at 6 Gy, 11% at 8 Gy and 4.5% at 10 Gy of survival populations to compared with non-irradiated cells (Fig. 1D). Whereas, bioluminescence activity of irradiated cells was 122% at 4 Gy, 224% at 6 Gy, 285% at 8 Gy and 276% at 10 Gy with dramatic increase compared to non-irradiated cells. After 6-Gy dosed irradiation, a small number of cells survived and slowly repopulated after irradiation at 4 days (Fig. 2A, left side). In sphere-formed condition (SC), sphere numbers were similar between irradiated and non-irradiated cells, but the sphere sizes of irradiated cells were larger than non-irradiated cells (Fig. 2A, right side).

**Comparison of CD44 and CD24 expression with irradiated subset and CD44 rich subset by sphere formation.** In irradiated condition, the CD24 presented cell population was decreased, but CD44 presented cell population was increased. The sphere formed cells and irradiated sphere formed cells were decreased in CD24 presented cells and increased in CD44 presented cells. Especially, irradiated sphere formed cells were 15% of the CD24 presented population decrease and 12% of the CD44 increased population (Fig. 2B).
bioluminescence activity of treated cells demonstrated an increased pattern (Fig. 2C, P<0.0001), the irradiated spheres were 3.2-fold increased compared to non-treated cells.

**Induced CD44 subset in spheres by irradiation and similarity between these subsets and CSCs.** CD44 expression of MCF-CL cells under irradiation, sphere formation culture or both treated conditions showed higher fluorescence intensity than non-treated cells. In particular, irradiated and sphere formed cells (cancer stem-like cells) had the strongest signals of CD44-Cy3 conjugated antibodies (Fig. 3A and C; 2.4-fold increase, P<0.0027). Also, CD133 expression was similar to CD44 (Fig. 3B and D; 3.2-fold increase, P<0.0001). The CD44 and fLuc gene expression levels were slightly increased, and CD133, OCT4 and Nanog were increased in treated cells in RT-PCR (Fig. 2D).

**In vivo monitoring of increased CD44 expression by irradiation.** Initial BLI signal with MCF-CL cell injected mouse (non-IR) was ~5x10^5 p/s/cm^2/sr. The bioluminescence signals in MCF-CL group (2.15x10^6 p/s/cm^2/sr) were higher than in non-irradiated group (2x10^5 p/s/cm^2/sr) immediately after irradiation (day 0). The BLI signals of irradiated group gradually became stronger than non-irradiated group and were shown to be relatively strong for 3 days. After 4 days, BLI signal intensity of irradiated group was higher ~3-fold (1.2x10^7 p/s/cm^2/sr) than non-irradiated group (4.4x10^6 p/s/cm^2/sr) (Fig. 4B, P<0.0001 on Student’s t-test).

**Radio-resistance of Stem-like subsets and effect of CD44 depletion to radio-resistance in vitro.** CD44+ subset showed higher bioluminescence activity (~2-fold) than CD44low subset (Fig. 5B). Two subsets showed different aspects by irradiation in survival population. As the irradiation dose increases, the surviving fraction of CD44+ or CD44low subsets was similarly decreased, but in CD44low subset, the width of decrease of surviving fraction was more than CD44+ subset (Fig. 5A, P<0.0001). After 6 Gy irradiation, CD44+ subset survival was 20%, and CD44low subset was survived 13% (data not shown). The bioluminescence activity of CD44+ subset was increased by about twice the CD44low subset with 6 Gy dose of irradiation (Fig. 5B). For the radio-resistance by CD44 expression, survival fraction of CD44 siRNA treated MCF7-CL was measured after irradiation of each dose. Survival fraction of CD44 siRNA treated MCF7-CL was 3-fold decreased compared to that of non-treated MCF7-CL at 4 Gy dose of irradiation (P<0.0089) (Fig. 5C).

**In vivo monitoring of CD44 expression and tumor growth from stem-like subset, and BLI after irradiation in breast cancer mouse model.** Initially, there was a significant difference between the two groups, and the difference was gradually increased with time elapse. In CD44+ group, tumor growth started to be recognized by the naked eye after 7 days (Fig. 5D). After 28 days, we observed a total of five tumors in the CD44+ mice and two tumors in the CD44low mice (n=5 transplants
for both conditions). The bioluminescence activity and tumor volume in CD44+ group was 3.3-fold (Fig. 5E, P<0.017) and ~44-fold (Fig. 5F, P<0.0001) higher than those of CD44 low group, respectively. In order to assess the BLI signal change by irradiation, we compared the irradiated and non-irradiated MCF7-CL tumor mouse models (Fig. 6A). After irradiation to the CD44+ tumor, BLI signal was decreased initially, but it was restored and started to increase time-dependently, compared to the non-irradiated group (Fig. 6B), whereas BLI signal of irradiated CD44 low tumor changed only slightly. In immunohistochemical study, the expression of CD44 and luciferase showed high correlation in CD44+ MCF-CL tumor (Fig. 6C). Also, irradiated tumor usually had a higher CD44 and luciferase expression level than non-irradiated tumor.
Discussion

A recent study discovered that CD44 is a marker which is significantly correlated with response to radiotherapy both at the mRNA and protein levels, in the early stage larynx cancer patients (24,25). In agreement with the previous research, this study found correlation between the breast cancer cell CD44 expression and \( \gamma \)-irradiation. We also concluded that CD44 mRNA level of breast cancer cells is closely connected with \( \gamma \)-irradiation. Additionally, increase in irradiation caused reduction in cell survival population, but the luciferase activity was accelerated by increasing BLI signal (26). It is foreseeable that it induces other genes associated with cancer stem cells (CSCs) as well. Also, we found an increased expression of CD133, OCT4 and Nanog (27). According to these results, the irradiation guided the cells to have similar characteristics as CSCs or survival cells which had similar characteristic to CSCs (6,14,15).

We hypothesized that CD44 depletion was affected by radio-resistance similarly to CSC. To identify the correla-
tion between radio-resistance and CD44, one group of cells containing plenty of CD44, and another group with shortage of CD44 were evaluated. We confirmed the increase in survival rate in the CD44+ cells and also, a decreased survival ratio on normal cells, which were intentionally treated with shortage of CD44 using siRNA (22).

We also verified changed expression of CD44, by irradia-

\[ \text{tion in vivo} \]

\[ \text{using mouse tumor model with fLuc. The use of bioluminescence as an optical marker for gene expression is a rapidly evolving technique of biomedical research, and it has been recently extended to non-invasive, real-time analysis of molecular events in intact cells and living animals (19,28,29).} \]

The bioluminescence signal gradually increased and reduced as time passed, in implant and irradiation. According to this clearer data, increase in CD44 expression, is strongly correlated with irradiation in vivo (15,21). These results suggest that the irradiated condition could actually enrich the cells with a CD44+ phenotype (19,28,29).

In recent studies, the cells in the CD44+/CD24low subpopulation have been shown to express higher levels of pro-invasive genes and have highly invasive properties (16). The solid tumor contains CD44+ expression tissue similar to breast cancer, pancreatic cancer, gastric cancer, and colorectal cancer, in the tumor formation probability in a mouse model and character-

ization is similar to CSCs (30). Accordingly, successful cancer treatment would need to detect and eliminate these CSCs (34). We have observed that CD44+ cells from breast cancer cells are significantly enriched in sphere-formed culture or through irradiation, suggesting that CD44+ cell subsets are more likely CSCs and to undergo cancer formation than CD44- low cells (31-33). Tumor initiation and growth are more rapid in CD44-positive cells. In a previous study (20), bioluminescence imaging was used to observe differences between CSC and non-CSC growth. Consequently, we found that breast cancer cells containing plenty of CD44 had more rapid formation and growth of tumors, compared to CD44low cells. However, BLI
signal of CD44low tumors increased by tumor formation and growth. We concluded that the tumor formation and growth could be predicted by monitoring of CD44 expression. In in vivo imaging data, we visualized phenomena that had been previously appreciated with irradiation, BLI and tumor volume in MCF7-CL tumor model. The tumors commonly increased BLI signal and growth, but after irradiation, they showed rapid increase of BLI signal, and reduced tumor volume (4). The CD44 expression in MCF7-CL tumor model was rapidly increased until 5 days after irradiation, and the reduced volume of tumor was also sustained. Therefore, we verified an increased CD44 expression correlated with increase in radio-sensitivity (7,27). It is possible that assessment of curability of a cancer may not only be the existing therapy, but also novel radiotherapy-dependent on the radio-sensitivity of intrinsic and induced BCSCs.

The limitation of luciferase imaging system is that it is not approved for clinical use. However, reporter gene is like near-infrared fluorescence gene, non-toxic to human, it is more widespread in clinical application of optical imaging. Despite hundreds of published studies on CD44 in the past, no consensus of opinion has been reached as of today, apart from that it plays some role in tumor progression, and that the overwhelming majority of studies failed to take CD44 into consideration. In conclusion, we developed a CD44 monitoring system which enables to inducible CD44 expression in breast cancer in vivo. This CD44 promoter-fLuc imaging system could be useful for monitoring of breast cancer stem cells in breast cancer during radio- or chemotherapy.

Acknowledgements

This study was supported by the Korea Science and Engineering Foundation (KOSEF) grant (grant nos. NRF-2012M2A2A7013480 and 2011-0030162) and funded by the Korean government (Ministry of Education, Science and Technology; MEST).

References

1. Gaffan J, Dacre J and Jones A; Educating undergraduate medical students about oncology. A literature review. J Clin Oncol 24: 1932-1939, 2006.
2. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
3. Lagasse E: Cancer stem cells with genetic instability: The best of both past, no consensus of opinion has been reached as of today, apart from that it plays some role in tumor progression, and that the overwhelming majority of studies failed to take CD44 into consideration. In conclusion, we developed a CD44 monitoring system which enables to inducible CD44 expression in breast cancer in vivo. This CD44 promoter-fLuc imaging system could be useful for monitoring of breast cancer stem cells in breast cancer during radio- or chemotherapy.

Acknowledgements

This study was supported by the Korea Science and Engineering Foundation (KOSEF) grant (grant nos. NRF-2012M2A2A7013480 and 2011-0030162) and funded by the Korean government (Ministry of Education, Science and Technology; MEST).

References

1. Gaffan J, Dacre J and Jones A; Educating undergraduate medical students about oncology. A literature review. J Clin Oncol 24: 1932-1939, 2006.
2. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
3. Lagasse E: Cancer stem cells with genetic instability: The best of both...
30. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.

31. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, et al: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679, 2008.

32. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270, 2003.

33. Gupta PB, Chaffer CL and Weinberg RA: Cancer stem cells: Mirage or reality? Nat Med 15: 1010-1012, 2009.

34. Fábián Á, Vereb G and Szöllösi J: The hitchhikers guide to cancer stem cell theory: Markers, pathways and therapy. Cytometry A 83: 62-71, 2013.